Fulcrum Therapeutics and Slate Medicines have signed a definitive agreement to merge in an all-stock transaction backed by a $245m private placement financing from a syndicate of healthcare investors.
The combined organisation, which will operate as Slate Medicines, is expected to be listed on Nasdaq under the "SLTE" ticker symbol.
Following completion of the merger, the new entity will focus on developing Slate's pipeline of migraine treatments, with SLTE-1009 as its lead candidate.
This clinical-stage subcutaneous anti- pituitary adenylate cyclase-activating peptide / vasoactive intestinal peptide (PACAP/VIP) monoclonal antibody is intended for the prevention of migraine and other headache disorders.
The financing is expected to support operations through 2029, enabling progress of SLTE-1009 through Phase I studies in healthy volunteers and a Phase II dose-range finding study in patients with migraine.
#phase #expected #peptide #therapeutics
The combined organisation, which will operate as Slate Medicines, is expected to be listed on Nasdaq under the "SLTE" ticker symbol.
Following completion of the merger, the new entity will focus on developing Slate's pipeline of migraine treatments, with SLTE-1009 as its lead candidate.
This clinical-stage subcutaneous anti- pituitary adenylate cyclase-activating peptide / vasoactive intestinal peptide (PACAP/VIP) monoclonal antibody is intended for the prevention of migraine and other headache disorders.
The financing is expected to support operations through 2029, enabling progress of SLTE-1009 through Phase I studies in healthy volunteers and a Phase II dose-range finding study in patients with migraine.
#phase #expected #peptide #therapeutics
28 days ago
